Skip to content
OpenCapital
Get started

Opus Genetics IRD Derivative Liabilities (Non-Current)

Derivative Liabilities (Non-Current) at other companies

4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$370K+14.9%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's derivative liabilities (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's derivative liabilities (non-current)?
Opus Genetics (IRD) reported derivative liabilities (non-current) of $77.35M in Q1 2026.
What does derivative liabilities (non-current) mean?
This represents the fair value of financial instruments, such as warrants or embedded conversion features, that are classified as liabilities and have settlement dates extending beyond one year. These instruments often arise from complex financing arrangements or equity-linked contracts. Changes in this balance reflect the revaluation of these obligations based on market conditions and the company's underlying equity performance.